Magalhães Fernanda Pedreira, Sousa Luciene Barbosa de, Oliveira Lauro Augusto de
Department of Ophthalmology, Universidade Federal de São Paulo, Brazil.
Arq Bras Oftalmol. 2012 May-Jun;75(3):218-22. doi: 10.1590/s0004-27492012000300016.
Regardless of significant progress in the field of corneal transplantation to treat corneal opacification, some cases of corneal blindness still present a poor prognosis for conventional penetrating keratoplasty. In patients with repeated graft failure and/or with severe ocular surface disease, the Boston type I keratoprosthesis (type I BKPro) has become a viable option. Modifications in its design and postoperative management have improved the long-term outcomes of visual acuity, retention, and postoperative infection rates. These advances made the type I BKPro be considered a safe alternative for visual rehabilitation in many patients with corneal pathologies. However, postoperative handle of chronic comorbidities, such as glaucoma, is still critical for preserving the visual gains achieved with BKPro.
尽管在角膜移植治疗角膜混浊领域取得了显著进展，但一些角膜盲病例对于传统穿透性角膜移植术而言预后仍然较差。对于反复移植失败和/或患有严重眼表疾病的患者，波士顿I型人工角膜（I型BKPro）已成为一种可行的选择。其设计和术后管理的改进提高了视力、存留率和术后感染率的长期效果。这些进展使I型BKPro被认为是许多角膜病变患者视力康复的安全替代方案。然而，术后处理慢性合并症，如青光眼，对于维持BKPro所取得的视力改善仍然至关重要。
